| pubmed-article:9065919 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0751967 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0032863 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C1441506 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C1515364 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C0456644 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C1552430 | lld:lifeskim |
| pubmed-article:9065919 | lifeskim:mentions | umls-concept:C1555766 | lld:lifeskim |
| pubmed-article:9065919 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:9065919 | pubmed:dateCreated | 1997-5-23 | lld:pubmed |
| pubmed-article:9065919 | pubmed:abstractText | Inhomogeneous patient samples have been used in previous studies to determine the power of magnetic resonance imaging (MRI) for trial monitoring in multiple sclerosis (MS). These power-calculations might not be applicable to the active relapsing-remitting patient who is preferably included in trials. In order to reevaluate the power-calculations for MRI in the monitoring of treatment in strictly relapsing-remitting MS and to compare the power of different trial designs we studied 12 relapsing-remitting MS patients prospectively for a median period of 12 months using monthly clinical assessments and gadolinium-enhanced MRI. A median number of two clinical relapses/patient occurred of which a median of one was treated with steroids. A median of 1.59 new lesions/scan/patient was detected (range 0-8). The total number of new active lesions correlated significantly with study period relapses (SRCC = 0.72, P = 0.023). Computer simulations using the bootstrap technique yielded mostly lower power values for a parallel groups design than in previous studies except for short follow-periods in larger samples. In this-sample the open cross-over design was found to be between 20 and 40% more powerful. Results of power-calculations are clearly sample dependent implying that for treatment trial monitoring using MRI in relapsing-remitting MS conservative sample size estimates are to be used. In an active patient group open cross-over trial designs could be a very powerful alternative to parallel groups design. | lld:pubmed |
| pubmed-article:9065919 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9065919 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9065919 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9065919 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9065919 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9065919 | pubmed:issn | 1352-4585 | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:HommesO ROR | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:ValkJJ | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:UDAYY | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:PolmanC HCH | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:NautaJ JJJ | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:BarkhofFF | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:FrequinS TST | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:TruyenLL | lld:pubmed |
| pubmed-article:9065919 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:9065919 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9065919 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:9065919 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9065919 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9065919 | pubmed:pagination | 283-90 | lld:pubmed |
| pubmed-article:9065919 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:meshHeading | pubmed-meshheading:9065919-... | lld:pubmed |
| pubmed-article:9065919 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9065919 | pubmed:articleTitle | Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. | lld:pubmed |
| pubmed-article:9065919 | pubmed:affiliation | Dutch MR centre for MS research, Academic Hospital Vrije Universiteit, Amsterdam. | lld:pubmed |
| pubmed-article:9065919 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9065919 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9065919 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9065919 | lld:pubmed |
